查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1534247

全球腎癌藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Kidney Cancer Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

全球腎癌藥物市場需求預計將從 2023 年的 67.2 億美元達到近 116.1 億美元的市場規模，2024-2032 年研究期間複合年成長率為 6.26%。

腎癌藥物是指用於治療腎癌（也稱為腎細胞癌（RCC））的藥物。這些藥物包括旨在抑制腎臟癌細胞生長和擴散的標靶療法、免疫療法和化療藥物。標靶治療通常會阻斷參與癌細胞增殖和血管生成的特定分子，而免疫療法則增強免疫系統識別和破壞癌細胞的能力。在某些情況下，化療藥物也可用於殺死快速分裂的癌細胞。治療的選擇取決於癌症分期、腫瘤中存在的基因突變以及患者的整體健康狀況等因素。

市場動態

全球腎癌發生率不斷上升，加上人們所認知的提高和早期檢測工作的發展，正在推動對有效腎癌藥物的需求。腎癌是全球十大最常見癌症之一，需要不斷創新治療方法以改善患者預後。分子生物學和基因分析的進步導致了專門針對與腎臟癌相關的分子改變的標靶療法的發展。標靶治療，包括酪胺酸激酶抑制劑 (TKI) 和哺乳動物雷帕黴素靶點 (mTOR) 抑制劑，已證明能夠有效抑制晚期腎細胞癌患者的癌細胞生長並延長無惡化存活期。此外，免疫療法徹底改變了腎臟癌的治療模式，特別是釋放免疫系統攻擊癌細胞的檢查點抑制劑。針對程序性細胞死亡蛋白1 (PD-1) 和細胞毒性T 淋巴細胞相關蛋白4 (CTLA-4) 的藥物在臨床試驗中顯示出良好的結果，為對傳統治療無反應的患者提供了新的治療替代方案。此外，製藥公司和研究機構之間的合作推動了腎癌藥物開發的創新。合作夥伴關係的重點是識別新型生物標記、探索聯合療法以及進行臨床試驗，以擴大治療選擇並改善患者的治療結果。然而，創新性腎癌藥物的取得可能會受到監管障礙、報銷政策和負擔能力問題的限制，這可能會抑制市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球腎癌藥物市場的各個細分市場進行了包容性評估。腎癌藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

腎癌藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按癌症類型

  • 腎臟細胞癌（RCC）
  • 移行細胞癌
  • 腎母細胞瘤
  • 腎臟肉瘤

透過治療

  • 標靶治療
  • 免疫療法
  • 化療
  • 其他療法

按藥物類別

  • 血管新生抑制劑
  • 單株抗體
  • 馬達抑制劑
  • 細胞激素免疫療法（IL-2）
  • 其他藥物類別

依給藥途徑

  • 口服
  • 靜脈
  • 皮下

按配銷通路

  • 醫院藥房
  • 實體店面
  • 電子商務

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲腎癌藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。腎臟癌藥物市場的主要參與者包括 Active Biotech AB、Amgen Inc.、Astellas Pharma Inc.、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Company、Eisai Co. Ltd.、Exelixis Inc.、F. Hoffmann-La羅氏有限公司、基因泰克公司、葛蘭素史克公司、赫爾辛醫療保健公司、強生服務公司、默克公司、諾華公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：腎癌藥物 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按癌症類型分類的市場吸引力分析
    • 按治療方法進行的市場吸引力分析
    • 按藥品類別分類的市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 按配銷通路分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球腎癌藥物市場分析：按癌症類型

  • 按癌症類型概述
  • 按癌症類型進行歷史和預測數據分析
  • 腎臟細胞癌（RCC）
  • 移行細胞癌
  • 腎母細胞瘤
  • 腎臟肉瘤

第 6 章：全球腎癌藥物市場分析：依治療方法

  • 治療概述
  • 按治療進行歷史和預測數據分析
  • 標靶治療
  • 免疫療法
  • 化療
  • 其他療法

第 7 章：全球腎癌藥物市場分析：依藥物類別

  • 按藥物類別概述
  • 按藥物類別進行歷史和預測數據分析
  • 血管新生抑制劑
  • 單株抗體
  • 馬達抑制劑
  • 細胞激素免疫療法（IL-2）
  • 其他藥物類別

第 8 章：全球腎癌藥物市場分析：依給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行歷史和預測資料分析
  • 口服
  • 靜脈
  • 皮下

第 9 章：全球腎癌藥物市場分析：按分銷管道

  • 配銷通路概覽
  • 按配銷通路進行歷史和預測資料分析
  • 醫院藥房
  • 實體店面
  • 電子商務

第 10 章：全球腎癌藥物市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 11 章：腎癌藥品公司的競爭格局

  • 腎癌藥物市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 12 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Active Biotech AB
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Amgen Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Astellas Pharma Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • AstraZeneca PLC
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bayer AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bristol-Myers Squibb Company
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Eisai Co. Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Exelixis Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • F. Hoffmann-La Roche Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Genentech Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • GSK Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Helsinn Healthcare SA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Johnson & Johnson Services Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Merck & Co. Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Novartis AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR112115310

The global demand for Kidney Cancer Drugs Market is presumed to reach the market size of nearly USD 11.61 Billion by 2032 from USD 6.72 Billion in 2023 with a CAGR of 6.26% under the study period 2024-2032.

Kidney cancer drugs refer to pharmaceutical agents used in the treatment of kidney cancer, also known as renal cell carcinoma (RCC). These drugs include targeted therapies, immunotherapies, and chemotherapy agents designed to inhibit the growth and spread of cancer cells in the kidneys. Targeted therapies typically block specific molecules involved in cancer cell proliferation and angiogenesis, while immunotherapies enhance the immune system's ability to recognize & destroy cancer cells. Chemotherapy drugs may also be used in certain cases to kill rapidly dividing cancer cells. The choice of treatment depends on factors such as cancer stage, genetic mutations present in the tumor, and the patient's overall health.

MARKET DYNAMICS

The rising incidence of kidney cancer globally, coupled with increasing awareness and early detection efforts, is driving demand for effective kidney cancer drugs. Kidney cancer is among the top ten most common cancers worldwide, necessitating continued innovation in treatment approaches to improve patient outcomes. Advancements in molecular biology and genetic profiling have led to the development of targeted therapies that specifically address molecular alterations associated with kidney cancer. Targeted therapies, including tyrosine kinase inhibitors (TKIs) & mammalian target of rapamycin (mTOR) inhibitors, have demonstrated efficacy in inhibiting cancer cell growth and prolonging progression-free survival in individuals diagnosed with advanced renal cell carcinoma. Moreover, immunotherapy has revolutionized the treatment landscape for kidney cancer, particularly checkpoint inhibitors that unleash the immune system to attack cancer cells. Drugs targeting programmed cell death protein 1 (PD-1) & cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown promising results in clinical trials, offering new therapeutic alternatives for patients who do not respond to conventional treatments. Furthermore, collaborative efforts between pharmaceutical companies & research institutions drive innovation in developing kidney cancer drugs. Partnerships focus on identifying novel biomarkers, exploring combination therapies, and conducting clinical trials to expand treatment options and improve patient outcomes. However, access to innovative kidney cancer drugs can be limited by regulatory hurdles, reimbursement policies, and affordability issues, which may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Kidney Cancer Drugs. The growth and trends of Kidney Cancer Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Kidney Cancer Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Cancer Type

  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Cancer
  • Wilms Tumor
  • Renal Sarcoma

By Therapy

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Other Therapies

By Drug Class

  • Angiogenesis Inhibitors
  • Monoclonal Antibodies
  • Mtor Inhibitors
  • Cytokine Immunotherapy (IL-2)
  • Other Drug Classes

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

By Distribution Channel

  • Hospital Pharmacy
  • Brick and Mortar
  • E-Commerce

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Kidney Cancer Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Kidney Cancer Drugs market include Active Biotech AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co. Ltd., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Plc, Helsinn Healthcare SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. KIDNEY CANCER DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Cancer Type
    • 3.7.2 Market Attractiveness Analysis By Therapy
    • 3.7.3 Market Attractiveness Analysis By Drug Class
    • 3.7.4 Market Attractiveness Analysis By Route of Administration
    • 3.7.5 Market Attractiveness Analysis By Distribution Channel
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY CANCER TYPE

  • 5.1. Overview By Cancer Type
  • 5.2. Historical and Forecast Data Analysis By Cancer Type
  • 5.3. Renal Cell Carcinoma (RCC) Historic and Forecast Sales By Regions
  • 5.4. Transitional Cell Cancer Historic and Forecast Sales By Regions
  • 5.5. Wilms Tumor Historic and Forecast Sales By Regions
  • 5.6. Renal Sarcoma Historic and Forecast Sales By Regions

6. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY THERAPY

  • 6.1. Overview By Therapy
  • 6.2. Historical and Forecast Data Analysis By Therapy
  • 6.3. Targeted Therapy Historic and Forecast Sales By Regions
  • 6.4. Immunotherapy Historic and Forecast Sales By Regions
  • 6.5. Chemotherapy Historic and Forecast Sales By Regions
  • 6.6. Other Therapies Historic and Forecast Sales By Regions

7. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 7.1. Overview By Drug Class
  • 7.2. Historical and Forecast Data Analysis By Drug Class
  • 7.3. Angiogenesis Inhibitors Historic and Forecast Sales By Regions
  • 7.4. Monoclonal Antibodies Historic and Forecast Sales By Regions
  • 7.5. Mtor Inhibitors Historic and Forecast Sales By Regions
  • 7.6. Cytokine Immunotherapy (IL-2) Historic and Forecast Sales By Regions
  • 7.7. Other Drug Classes Historic and Forecast Sales By Regions

8. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 8.1. Overview By Route of Administration
  • 8.2. Historical and Forecast Data Analysis By Route of Administration
  • 8.3. Oral Historic and Forecast Sales By Regions
  • 8.4. Intravenous Historic and Forecast Sales By Regions
  • 8.5. Subcutaneous Historic and Forecast Sales By Regions

9. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 9.1. Overview By Distribution Channel
  • 9.2. Historical and Forecast Data Analysis By Distribution Channel
  • 9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 9.4. Brick and Mortar Historic and Forecast Sales By Regions
  • 9.5. E-Commerce Historic and Forecast Sales By Regions

10. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE KIDNEY CANCER DRUGS COMPANIES

  • 11.1. Kidney Cancer Drugs Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF KIDNEY CANCER DRUGS INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Active Biotech AB
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Amgen Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Astellas Pharma Inc.
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. AstraZeneca PLC
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. Bayer AG
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. Bristol-Myers Squibb Company
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Eisai Co. Ltd.
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. Exelixis Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. F. Hoffmann-La Roche Ltd.
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Genentech Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. GSK Plc
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Helsinn Healthcare SA
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments
  • 12.15. Johnson & Johnson Services Inc.
    • 12.15.1 Company Overview
    • 12.15.2 Company Revenue
    • 12.15.3 Products
    • 12.15.4 Recent Developments
  • 12.16. Merck & Co. Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Company Revenue
    • 12.16.3 Products
    • 12.16.4 Recent Developments
  • 12.17. Novartis AG
    • 12.17.1 Company Overview
    • 12.17.2 Company Revenue
    • 12.17.3 Products
    • 12.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Cancer Type (USD MN)
  • Renal Cell Carcinoma (RCC) Market Sales By Geography (USD MN)
  • Transitional Cell Cancer Market Sales By Geography (USD MN)
  • Wilms Tumor Market Sales By Geography (USD MN)
  • Renal Sarcoma Market Sales By Geography (USD MN)
  • Analysis By Therapy (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunotherapy Market Sales By Geography (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Other Therapies Market Sales By Geography (USD MN)
  • Analysis By Drug Class (USD MN)
  • Angiogenesis Inhibitors Market Sales By Geography (USD MN)
  • Monoclonal Antibodies Market Sales By Geography (USD MN)
  • Mtor Inhibitors Market Sales By Geography (USD MN)
  • Cytokine Immunotherapy (IL-2) Market Sales By Geography (USD MN)
  • Other Drug Classes Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Brick and Mortar Market Sales By Geography (USD MN)
  • E-Commerce Market Sales By Geography (USD MN)
  • Global Kidney Cancer Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Kidney Cancer Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Kidney Cancer Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Cancer Type
  • Market Attractiveness Analysis By Therapy
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Cancer Type (USD MN)
  • Renal Cell Carcinoma (RCC) Market Sales By Geography (USD MN)
  • Transitional Cell Cancer Market Sales By Geography (USD MN)
  • Wilms Tumor Market Sales By Geography (USD MN)
  • Renal Sarcoma Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunotherapy Market Sales By Geography (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Other Therapies Market Sales By Geography (USD MN)
  • Global Market Analysis By Drug Class (USD MN)
  • Angiogenesis Inhibitors Market Sales By Geography (USD MN)
  • Monoclonal Antibodies Market Sales By Geography (USD MN)
  • Mtor Inhibitors Market Sales By Geography (USD MN)
  • Cytokine Immunotherapy (IL-2) Market Sales By Geography (USD MN)
  • Other Drug Classes Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Brick and Mortar Market Sales By Geography (USD MN)
  • E-Commerce Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.